PMID- 35210284
OWN - NLM
STAT- MEDLINE
DCOM- 20220323
LR  - 20221207
IS  - 2052-4897 (Electronic)
IS  - 2052-4897 (Linking)
VI  - 10
IP  - 1
DP  - 2022 Feb
TI  - Efficacy of a meal sequence in patients with type 2 diabetes: a systematic review 
      and meta-analysis.
LID - 10.1136/bmjdrc-2021-002534 [doi]
LID - e002534
AB  - INTRODUCTION: This systematic review investigated the efficacy of a meal 
      sequence, the carbohydrate-later meal pattern (CL), on type 2 diabetes mellitus 
      (T2DM). RESEARCH DESIGN AND METHODS: We searched the Cochrane Central Register of 
      Controlled Trials, MEDLINE, Embase, WHO International Clinical Trials Registry 
      Platform, and ClinicalTrials.gov until April 2020 to perform meta-analyses using 
      random-effects models. Primary outcomes were hemoglobin A1c (HbA1c) and quality 
      of life. Secondary outcomes were plasma concentrations of glucose, insulin and 
      incretin 120 min after a meal, and any adverse outcomes. The revised Cochrane 
      risk-of-bias tool and Grading of Recommendations, Assessment, Development, and 
      Evaluation approach were used to assess the quality of individual studies and the 
      body of evidence, respectively. The present study was registered in the UMIN 
      Clinical Trials Registry. RESULTS: We included 230 participants in eight trials, 
      including both trials that examined long-term changes (more than 2 months and 
      less than 2 years) and short-term changes (in 2-hour postprandial values). CL 
      resulted in a slight to no difference in HbA1c (mean difference (MD), -0.21% in 
      the intervention group; 95% CI -0.44% to+0.03%), plasma glucose (MD,+4.94 mg/dL; 
      95% CI -8.34 mg/dL to +18.22 mg/dL), plasma insulin (MD, -3.63 muIU/mL; 95% CI 
      -11.88 muIU/mL to +4.61 muIU/mL), plasma GLP-1 (MD, +0.43 pmol/L; 95% CI -0.69 
      pmol/L to +1.56 pmol/L), and plasma GIP (MD, -2.02 pmol/L; 95% CI -12.34 pmol/L 
      to +8.31 pmol/L). All of these outcomes were of low-certainty evidence or very 
      low-certainty evidence. None of the trials evaluated quality of life or adverse 
      events. CONCLUSIONS: There was no evidence for the potential efficacy of 
      recommending CL beyond standard dietary advice on T2DM. TRIAL REGISTRATION 
      NUMBER: UMIN000039979.
CI  - (c) Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No 
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Okami, Yukiko
AU  - Okami Y
AUID- ORCID: 0000-0002-5651-7872
AD  - NCD Epidemiology Research Center, Shiga University of Medical Science, Otsu, 
      Japan okami@belle.shiga-med.ac.jp.
AD  - Systematic Review Workshop Peer Support Group (SRWS-PSG), Osaka, Japan.
FAU - Tsunoda, Hideki
AU  - Tsunoda H
AD  - Systematic Review Workshop Peer Support Group (SRWS-PSG), Osaka, Japan.
AD  - Department of Family Medicine, University of Pittsburgh Medical Center Shadyside, 
      Pittsburgh, Pennsylvania, USA.
FAU - Watanabe, Jun
AU  - Watanabe J
AD  - Systematic Review Workshop Peer Support Group (SRWS-PSG), Osaka, Japan.
AD  - Department of Surgery, Division of Gastroenterological, General and Transplant 
      Surgery, Jichi Medical University, Shimotsuke, Japan.
AD  - Division of Community and Family Medicine, Jichi Medical University, Shimotsuke, 
      Japan.
FAU - Kataoka, Yuki
AU  - Kataoka Y
AD  - Systematic Review Workshop Peer Support Group (SRWS-PSG), Osaka, Japan.
AD  - Department of Internal Medicine, Kyoto Min-Iren Asukai Hospital, Kyoto, Japan.
AD  - Section of Clinical Epidemiology, Department of Community Medicine, Kyoto 
      University Graduate School of Medicine, Kyoto, Japan.
AD  - Department of Healthcare Epidemiology, Kyoto University Graduate School of 
      Medicine / School of Public Health, Kyoto, Japan.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Systematic Review
PL  - England
TA  - BMJ Open Diabetes Res Care
JT  - BMJ open diabetes research & care
JID - 101641391
RN  - 0 (Glycated Hemoglobin A)
RN  - 0 (Incretins)
RN  - 89750-14-1 (Glucagon-Like Peptide 1)
SB  - IM
MH  - *Diabetes Mellitus, Type 2/complications
MH  - Glucagon-Like Peptide 1
MH  - Glycated Hemoglobin
MH  - Humans
MH  - Incretins
MH  - Quality of Life
PMC - PMC8883221
OTO - NOTNLM
OT  - diabetes mellitus
OT  - diet
OT  - type 2
COIS- Competing interests: None declared.
EDAT- 2022/02/26 06:00
MHDA- 2022/03/24 06:00
PMCR- 2022/02/24
CRDT- 2022/02/25 05:33
PHST- 2021/08/14 00:00 [received]
PHST- 2022/02/02 00:00 [accepted]
PHST- 2022/02/25 05:33 [entrez]
PHST- 2022/02/26 06:00 [pubmed]
PHST- 2022/03/24 06:00 [medline]
PHST- 2022/02/24 00:00 [pmc-release]
AID - 10/1/e002534 [pii]
AID - bmjdrc-2021-002534 [pii]
AID - 10.1136/bmjdrc-2021-002534 [doi]
PST - ppublish
SO  - BMJ Open Diabetes Res Care. 2022 Feb;10(1):e002534. doi: 
      10.1136/bmjdrc-2021-002534.